Consequently, pharmaceutical companies must invest in educational initiatives to enhance understanding among both professionals and patients, fostering better adoption and utilization of GLP-1 receptor agonists in treatment regimens
Sohn EH, et al
The 24 individuals with obesity were taking a maintenance dose of GLP-1RA medication for weight loss ( N = 14, GLP-1RA group) for at least 30 days, or not taking any medication for weight loss ( N = 10, control group)
Given the findings from the LEAD clinical trials, how would you evaluate the trade-offs between liraglutides benefits (e.g., glycemic control, weight loss) and its potential side effects, such as nausea or pancreatitis
In addition to blood glucose level management, many of these have been shown to be effective in lowering weight
Manufacturers formulate weight loss patches using a range of ingredients